$2.46 Billion is the total value of Tekla Capital Management LLC's 194 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CLDX | Exit | Celldex Therapeutics, Inc. | $0 | – | -105,800 | -100.0% | -0.00% | – |
| NCNA | Exit | NuCana plcsponsored adr | $0 | – | -9,823 | -100.0% | -0.01% | – |
| EIDX | Exit | Eidos Therapeutics, Inc. | $0 | – | -27,900 | -100.0% | -0.02% | – |
| ONCE | Exit | Spark Therapeutics, Inc. | $0 | – | -10,772 | -100.0% | -0.02% | – |
| LXRX | Exit | Lexicon Pharmaceuticals, Inc.sponsored adr | $0 | – | -70,000 | -100.0% | -0.02% | – |
| ACHN | Exit | Achillion Pharmaceuticals, Inc. | $0 | – | -318,833 | -100.0% | -0.02% | – |
| A | Exit | Agilent Technologies, Inc. | $0 | – | -8,200 | -100.0% | -0.02% | – |
| LMAT | Exit | LeMaitre Vascular, Inc. | $0 | – | -27,150 | -100.0% | -0.03% | – |
| Exit | Takeda Pharmaceutical Co. Ltd.sponsored ads | $0 | – | -19,200 | -100.0% | -0.03% | – | |
| Exit | Egalet Corporationnote 5.50% 4/1/20 | $0 | – | -7,000,000 | -100.0% | -0.03% | – | |
| NITE | Exit | Nightstar Therapeutics plcadr | $0 | – | -98,929 | -100.0% | -0.05% | – |
| DERM | Exit | Dermira, Inc. | $0 | – | -161,579 | -100.0% | -0.05% | – |
| MTD | Exit | Mettler-Toledo International Inc. | $0 | – | -3,500 | -100.0% | -0.08% | – |
| WAT | Exit | Waters Corporation | $0 | – | -10,800 | -100.0% | -0.09% | – |
| INOV | Exit | Inovalon Holdings, Inc. | $0 | – | -176,163 | -100.0% | -0.11% | – |
| NVRO | Exit | Nevro Corp. | $0 | – | -68,760 | -100.0% | -0.11% | – |
| INVA | Exit | Innoviva, Inc. | $0 | – | -161,603 | -100.0% | -0.12% | – |
| LOXO | Exit | Loxo Oncology, Inc. | $0 | – | -24,595 | -100.0% | -0.15% | – |
| STE | Exit | STERIS plcshares | $0 | – | -48,003 | -100.0% | -0.22% | – |
| SHPG | Exit | Shire plcsponsored adr | $0 | – | -36,216 | -100.0% | -0.27% | – |
| Exit | Aegerion Pharmaceuticals, Inc.note 2.00% 8/15/19 | $0 | – | -13,000,000 | -100.0% | -0.42% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.